Glycopyrrolate / Formoterol bulk supplier for pharma manufacturers

Glycopyrrolate / Formoterol Suppliers & Bulk Manufacturers

Available Forms: Pressurized metered-dose inhaler (pMDI)

Available Strengths: Glycopyrrolate 9 mcg + Formoterol fumarate 4.8 mcg

Reference Brands: Bevespi Aerosphere(US)

Glycopyrrolate + Formoterol is a LAMA/LABA combination used for COPD maintenance treatment. Marketed as Bevespi Aerosphere in the U.S., it offers twice-daily bronchodilation via a metered-dose inhaler, helping improve lung function and reduce breathlessness in COPD patients. It is not intended for acute symptom relief.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Glycopyrrolate + Formoterol is a long-acting bronchodilator combination used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate, a LAMA, and Formoterol, a LABA, work together to relax airway muscles, improve airflow, and reduce symptoms like breathlessness. Marketed as Bevespi Aerosphere in the United States, this combination is delivered via a pressurized metered-dose inhaler (pMDI) and taken twice daily. It is not intended for acute symptom relief but provides long-term control of COPD symptoms. Bevespi Aerosphere helps enhance lung function, reduce exacerbations, and improve the overall quality of life for patients with moderate to severe COPD.

Glycopyrrolate / Formoterol — third party manufacturing & bulk supply

Glycopyrrolate / Formoterol is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glycopyrrolate / Formoterol is supplied as Pressurized metered-dose inhaler (pMDI) — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glycopyrrolate / Formoterol listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glycopyrrolate / Formoterol →

Back to Listing

Frequently Asked Questions

Glycopyrrolate / Formoterol is used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It helps improve lung function, reduce exacerbations, and relieve symptoms such as shortness of breath and wheezing.

This combination is made from glycopyrrolate (glycopyrronium bromide) and formoterol fumarate dihydrate. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that relaxes airway muscles by blocking acetylcholine receptors, while formoterol is a long-acting beta-2 agonist (LABA) that provides bronchodilation.

Common trade names include Bevespi Aerosphere (USA), and various regional or generic brands available in global markets.

The original product is marketed by AstraZeneca. It is also manufactured by multiple pharmaceutical companies globally as inhalation combination products.

The complete generic name is glycopyrronium bromide and formoterol fumarate dihydrate.

Brand names include Bevespi Aerosphere and various region-specific generic brands.

This combination is manufactured globally in countries such as the USA, EU nations, India, and other regions by both innovator and generic pharmaceutical companies.